IP Library Granted Patent US 10,774,373
Granted Patent B2
US 10,774,373 · App. 16/541,857 · Granted Sep 15, 2020

Compositions comprising glucosylated hydroxymethylated bases

Inventors: Anjana Rao (La Jolla, CA); Mamta Tahiliani (New York, NY); Kian Peng Koh (Jamaica Plain, MA); Suneet Agarwal (Belmont, MA); Aravind Iyer (Bethesda, MA)
Assignees: CHILDREN'S MEDICAL CENTER CORPORATION; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
C12Q1/6827C12Q1/26C12Q1/6806C12Q1/6869G01N33/5308C12N2501/70C12N2501/71C12Q2521/531C12Q2522/10C12Q2537/164C12Q2600/154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,774,373
App. No.
16/541,857
Granted
Sep 15, 2020
Kind
B2
Abstract

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

Claims (25)

1. An isolated nucleic acid from an extracellular fluid sample, wherein a hydroxymethylated cytosine of said isolated nucleic acid is glucosylated.

2. The nucleic acid of claim 1 , wherein said isolated nucleic acid comprises genomic DNA.

3. The nucleic acid of claim 1 , wherein said glucosylated hydroxymethylated cytosine is a glucosylated 5-hydroxymethlycytosine.

4. The nucleic acid of claim 1 , wherein a glucose of said glucosylated hydroxymethylated cytosine is labeled.

5. The nucleic acid of claim 1 , further comprising a guanine (G), an adenine (A), a thymine (T), a uracil (U), and a cytosine (C).

6. A double-stranded DNA, wherein a strand of said double-stranded DNA comprises said isolated nucleic acid of claim 1 .

7. A composition comprising said isolated nucleic acid of claim 1 and a nucleic acid sequence complementary to at least a portion of said isolated nucleic acid.

8. The composition of claim 7 , wherein said nucleic acid sequence, that is complementary to at least a portion of said isolated nucleic acid, is a population of nucleic acid sequences.

9. A composition comprising said isolated nucleic acid of claim 1 and a DNA polymerase.

10. A composition comprising said isolated nucleic acid of claim 1 and a solid support.

11. The composition of claim 10 , wherein said glucosylated hydroxymethylated cytosine is associated with said solid support.

12. The composition of claim 10 , wherein a moiety is associated with said glucosylated hydroxymethylated cytosine.

13. The composition of claim 12 , wherein said moiety is covalently coupled to said glucosylated hydroxymethylated cytosine.

14. The composition of claim 12 , wherein said moiety comprises a biotinyl group.

15. A method comprising: contacting said isolated nucleic acid of claim 1 with a moiety, wherein said moiety comprises a biotinyl group or a fluorophore.

16. A method comprising: isolating said isolated nucleic acid of claim 1 from a sample by affinity purification.

17. A method comprising: sequencing said isolated nucleic acid of claim 1 .

18. A composition comprising: (a) a glucosylated nucleic acid comprising a glucosylated 5-hydroxymethylcytosine; and (b) an isolated and purified dioxygenase enzyme or fragment thereof.

19. The composition of claim 18 , further comprising a co-factor.

20. The composition of claim 19 , wherein said co-factor comprises iron.

21. The composition of claim 18 , wherein said glucosylated nucleic acid is labeled.

22. A composition comprising: (a) glucosylated nucleic acid; and (b) an isolated and purified dioxygenase enzyme or said fragment thereof that is a TET family enzyme or fragment thereof.

23. The composition of claim 22 , further comprising a co-factor.

24. The composition of claim 23 , wherein said co-factor comprises iron.

25. The composition of claim 22 , wherein said glucosylated nucleic acid is labeled.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2020
From: RAO, ANJANA; TAHILIANI, MAMTA; KOH, KIAN PENG
To: IMMUNE DISEASE INSTITUTE, INC.
Reel/Frame 053266/0148 →
MERGER Recorded Jul 21, 2020
From: IMMUNE DISEASE INSTITUTE, INC.
To: THE CHILDREN'S HOSPITAL CORPORATION
Reel/Frame 053266/0161 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2020
From: THE CHILDREN'S HOSPITAL CORPORATION
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 053266/0180 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2020
From: AGARWAL, SUNEET
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 053266/0187 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2020
From: IYER, ARAVIND
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 053266/0191 →
Continuity (9)
Continuation 16012510 · Jun 19, 2018
Continuation 15341344 · Nov 2, 2016
Continuation 15193796 · Jun 27, 2016
Continuation 13795739 · Mar 12, 2013
Continuation 13120861
Provisional Application 61121844 · Dec 11, 2008
Provisional Application 61100995 · Sep 29, 2008
Provisional Application 61100503 · Sep 26, 2008
Related Publication 20190390261A1 · Dec 26, 2019
Cited By (12)
US 12,228,574 US 12,247,905 US 12,291,742 US 12,331,346 US 12,338,489 US 12,372,528 US 12,410,480 US 12,454,724 US 12,467,082 US 12,503,728 US 12,630,866 US 12,682,984